Natco Pharma
Natco Pharma Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Natco Pharma
Start SIPNatco Pharma Investment Rating
-
Master Rating:
-
Natco Pharma has an operating revenue of Rs. 2,406.00 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 10% is healthy, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 34 which is a POOR score indicating inconsistency in earnings, a RS Rating of 44 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 87 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 413 | 351 | 806 | 514 |
| Operating Expenses Qtr Cr | 346 | 281 | 426 | 552 |
| Operating Profit Qtr Cr | 68 | 70 | 379 | -38 |
| Depreciation Qtr Cr | 38 | 38 | 37 | 36 |
| Interest Qtr Cr | 3 | 2 | 3 | 4 |
| Tax Qtr Cr | 8 | 9 | 65 | -6 |
| Net Profit Qtr Cr | 37 | 38 | 308 | -61 |
Natco Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 12
- Bearish Moving Average
- ___
- 4
- 20 Day
- 545.79
- 50 Day
- 546.76
- 100 Day
- 561.19
- 200 Day
- 606.68
- 20 Day
- 548.09
- 50 Day
- 540.24
- 100 Day
- 553.75
- 200 Day
- 595.35
Natco Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 560.79 |
| Second Resistance | 570.47 |
| Third Resistance | 578.44 |
| RSI | 56.68 |
| MFI | 67.5 |
| MACD Single Line | 0.66 |
| MACD | 1.44 |
| Support | |
|---|---|
| First Resistance | 543.14 |
| Second Resistance | 535.17 |
| Third Resistance | 525.49 |
Natco Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 693,097 | 51,621,865 | 74.48 |
| Week | 332,197 | 22,489,737 | 67.7 |
| 1 Month | 405,085 | 25,901,107 | 63.94 |
| 6 Month | 276,029 | 16,432,022 | 59.53 |
Natco Pharma Result Highlights
Natco Pharma Synopsis
NSE-Medical-Diversified
Natco Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1767.80 Cr. and Equity Capital is Rs. 36.50 Cr. for the Year ended 31/03/2022. Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1981PLC003201 and registration number is 003201.| Market Cap | 10,145 |
| Sales | 2,084 |
| Shares in Float | 9.31 |
| No of funds | 210 |
| Yield | 0.99 |
| Book Value | 2.42 |
| U/D Vol ratio | 1.3 |
| LTDebt / Equity | |
| Alpha | -0.11 |
| Beta | 0.5 |
Natco Pharma
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 48.82% | 48.8% | 48.8% | |
| Mutual Funds | 8.18% | 7.63% | 6.75% | |
| Insurance Companies | 6.18% | 6.07% | ||
| Foreign Portfolio Investors | 11.73% | 11.67% | 11.65% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 19.83% | 20.14% | 18.45% | |
| Others | 5.26% | 5.69% | 14.35% |
Natco Pharma Management
| Name | Designation |
|---|---|
| Mr. V C Nannapaneni | Managing Director |
| Mr. Rajeev Nannapaneni | Director & CEO |
| Mr. T V Rao | Independent Director |
| Mr. G S Murthy | Chairman & Ind.Director |
| Mr. D G Prasad | Independent Director |
| Dr. M U R Naidu | Independent Director |
| Dr. Leela Digumarti | Independent Director |
| Mr. P S R K Prasad | Director & Exe. VP (Corp. Engg. Services) |
| Dr. Linga Rao Donthineni | Director & President (Tech. Affairs) |
| Mr. Pavan Bhat | Director |
Natco Pharma Forecast
Price Estimates
Natco Pharma FAQs
What is Share Price of Natco Pharma ?
Natco Pharma share price is ₹555 As on 30 March, 2023 | 13:16
What is the Market Cap of Natco Pharma ?
The Market Cap of Natco Pharma is ₹10144.7 Cr As on 30 March, 2023 | 13:16
What is the P/E ratio of Natco Pharma ?
The P/E ratio of Natco Pharma is 26.1 As on 30 March, 2023 | 13:16
What is the PB ratio of Natco Pharma ?
The PB ratio of Natco Pharma is 2.4 As on 30 March, 2023 | 13:16